Nextcure Stock Price, News & Analysis

NextCure, Inc. (Nasdaq: NXTC) has announced the discontinuation of its NC318 program after finding no responses in the trial's amended Phase 2 segment. The company will shift focus to its NC410, NC525, and NC762 programs, including an ongoing combination trial of NC410 with pembrolizumab and a Phase 1 trial of NC525 starting in early 2023. These strategic adjustments are anticipated to extend the company’s cash runway into mid-2025.

As of September 30, 2022, NextCure reported cash equivalents of $169.2 million, down from $219.6 million as of December 31, 2021, resulting in a net loss of $18.9 million for the quarter.

NextCure, Inc. (Nasdaq: NXTC) announced that Dr. Nicholas Short will present a Trials in Progress poster on NC525, a novel immunomedicine, at the upcoming American Society of Hematology (ASH) meeting in New Orleans. NC525 is designed to treat advanced myeloid leukemia (AML) by targeting LAIR-1, present on AML cells. Following promising preclinical results, NextCure has filed an IND application with the FDA and plans to initiate a Phase 1 clinical study in Q1 2023. The presentation is scheduled for December 12, 2022.

NextCure, Inc. (Nasdaq: NXTC) has appointed Dr. Lisa M. Coussens to its Scientific Advisory Board. Dr. Coussens is a proficient translational tumor immunologist with over 20 years of experience in cancer research. She will assist NextCure in enhancing its pipeline of immunomedicines. This strategic addition is expected to bolster NextCure's efforts in immuno-oncology, focusing on tumors and immune response mechanisms. Dr. Coussens' esteemed background includes leadership roles and numerous accolades, positioning her as a key asset for NextCure's future developments in cancer therapies.

NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company, announced its participation in the Society for Immunotherapy of Cancer (SITC) annual meeting from November 8-12, 2022. The company will present data from its Phase 1 clinical study of NC762 and an overview of its NC410 combination study. NC762 targets B7-H4 to inhibit tumor growth, while NC410 blocks immune suppression mediated by LAIR-1. The presentations aim to showcase advancements in NextCure’s immunomedicines aimed at treating cancer.

NextCure, Inc. (NASDAQ: NXTC), a clinical-stage biopharmaceutical company, has initiated a Phase 1b/2 clinical trial for NC410 in combination with Merck's KEYTRUDA® in patients with immune checkpoint refractory or naïve solid tumors. The study aims to explore NC410's potential in treating colorectal, esophageal, endometrial, and head and neck cancers. Key points include: NextCure sponsoring the trial, a supply agreement with Merck, and expected initial data release in mid-2023. NC410 aims to block immune suppression mediated by LAIR-1.

NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company, announced its presentation at the Ladenburg Thalmann Healthcare Conference in New York City on September 29 at 10 am ET. The event will include a live audio webcast available on the company’s website, with a replay accessible for 30 days post-event. NextCure focuses on developing first-in-class immunomedicines for cancer and immune-related diseases, utilizing its FIND-IO™ platform to identify novel treatment targets. The company aims to help patients unresponsive to existing therapies.

NextCure, Inc. (Nasdaq: NXTC) announced its Q2 2022 financial results, reporting cash reserves of $185.5 million, expected to fund operations through Q1 2024. The company is on track for updates from three clinical programs (NC318, NC410, and NC762) in H2 2022, along with an IND filing for NC525. Total cash, cash equivalents, and marketable securities decreased from $219.6 million at year-end 2021, driven by operational costs. Q2 R&D expenses rose to $12.8 million from $11.9 million last year, while general and administrative expenses fell to $5.3 million from $6.0 million.

NextCure (NASDAQ: NXTC) has published a paper detailing the development of an immunohistochemical assay for Siglec-15, a protein implicated in cancer's immunosuppressive environment. This research, conducted with Yale School of Medicine, presents data supporting the targeting of Siglec-15 in therapeutic candidates like NC318. The study shows high S15 expression in non-small cell lung cancer (NSCLC), indicating a potential pathway for future clinical trials. The assay's validation and scoring system hold promise for advancing patient selection in ongoing trials.

NextCure (NASDAQ: NXTC) presented promising data on NC410 at the 2022 ECM Pharmacology Congress in Copenhagen, showcasing its ability to remodel tumor extracellular matrix (ECM), enhance immune cell infiltration, and reduce tumor growth in humanized mouse models. This first-in-class immunomedicine targets LAIR-1, overcoming barriers to immunotherapy. Highlights include NC410's binding to collagen-rich areas and synergistic effects with PD-L1 targeting. Currently in a Phase 1/2 study for advanced solid tumors, NextCure anticipates updates in late 2022.